Targeting breast cancer metastasis with inhibitors of Id-1

Information

  • Research Project
  • 8516812
  • ApplicationId
    8516812
  • Core Project Number
    R43CA171415
  • Full Project Number
    1R43CA171415-01A1
  • Serial Number
    171415
  • FOA Number
    PA-12-088
  • Sub Project Id
  • Project Start Date
    5/1/2013 - 11 years ago
  • Project End Date
    4/30/2015 - 9 years ago
  • Program Officer Name
    HAIM, TODD E.
  • Budget Start Date
    5/1/2013 - 11 years ago
  • Budget End Date
    4/30/2015 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    5/1/2013 - 11 years ago
Organizations

Targeting breast cancer metastasis with inhibitors of Id-1

DESCRIPTION (provided by applicant): Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current first- line agents which are used to treat breast cancer metastasis primarily target tumor growth. These drugs produce only modest increases in survival in patients with aggressive metastatic cancers and have significant side effects. Currently, there are no available treatment options that can specifically and effectively inhibit tumor invasion and metastasis. Therefore, novel drug strategies are needed to treat this chronic, fatal and incurable condition. Our therapeutic strategy for the treatment of aggressive breast cancer is based on reducing Id-1 expression. Id-1 is a key regulator of the invasive and metastatic potential of breast and additional cancers. In this Phase I proposal our focus will be on the optimization of our lead compound to discover one or more analogs that down-regulate Id-1 expression and consequently inhibit breast cancer cell invasion and metastasis. We will also optimize these compounds so that they display a favorable ADME-Tox profile. The ultimate goal of this proposal is to develop a novel therapeutic approach for the treatment of metastatic human breast cancers by down-regulation of Id-1.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    289823
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:289823\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORGANIX, INC.
  • Organization Department
  • Organization DUNS
    161843057
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    018012029
  • Organization District
    UNITED STATES